Affymetrix and bioMerieux Extend Their Agreement on GeneChip(R) Technology to Breast Cancer Diagnostics
The agreement, made under the Powered by Affymetrix(TM) program, gives bioMerieux non-exclusive rights to Affymetrix' patented arrays, instrumentation systems and future improvements to these key technologies. Financial terms of the agreement were not disclosed.
Under the Powered by Affymetrix(TM) program, Affymetrix provides technology and expertise for products that are developed, branded and marketed by diagnostic companies. This includes the GeneChip System 3000Dx, which has been granted regulatory clearance by the U.S. Food and Drug Administration and CE marked in the European Union for in-vitro diagnostic use.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.